Related Experiment Video
Updated: Jun 12, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
[Etanercept and neoplasms]
A García-Rabasco1, J L Sánchez-Carazo, A Esteve
1Servicio de Dermatología, Consorcio Hospital General Universitario, Valencia, España. anagrabasco@gmail.com
Abstract:
The introduction of tumor necrosis factor (TNF) beta blockers has make it possible to obtain a significant advance in the control and knowledge of some inflammatory diseases, among them psoriasis. TNF is a cytokine that plays a key role in the control of infections and neoplasms. The increase of the risk of developing a neoplasm during the use of this group of drugs is one of the more debated adverse effects in the literature. We present the clinical case of one patient with long-course psoriasis who developed a breast adenocarcinoma after initiating treatment with etanercept. In this article, we provide a brief review on the possible associations existing between the use of anti-TNF therapy and the risk of the appearance of come neoplasms, among which leukemias, lymphomas and some solid tumors stand out.
Insights
Tumor necrosis factor (TNF) blockers significantly advance inflammatory disease treatment but may increase neoplasm risk. A psoriasis patient developed breast cancer after etanercept, highlighting this debated adverse effect.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Tumor necrosis factor (TNF) blockers represent a therapeutic advance for inflammatory diseases like psoriasis.
- TNF is crucial for immune surveillance against infections and neoplasms.
Observation:
- A long-standing psoriasis patient developed breast adenocarcinoma following etanercept treatment.
- This case highlights a potential adverse effect of anti-TNF therapy.
Findings:
- The use of anti-TNF agents, including etanercept, is debated regarding an increased risk of neoplasm development.
- Literature suggests associations between anti-TNF therapy and certain cancers, such as leukemias, lymphomas, and solid tumors.
Implications:
- Clinicians should carefully weigh the benefits and risks of anti-TNF therapy in patients with inflammatory conditions.
- Further research is warranted to elucidate the precise relationship between anti-TNF agents and neoplasm risk.
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Psychoneuroimmunology: Diabetes and Cancer
